Barbara Castelnuovo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Barbara Castelnuovo has a total of 432 co-authors. Here are the top co-authors by number of shared publications:
- Agnes Kiragga
African Population and Health Research Center
20 shared publications - Christine Sekaggya-Wiltshire
Makerere University Infectious Diseases Institute Department of Research Kampala
16 shared publications - Rosalind Parkes-Ratanshi
Infectious Disease Institute, Makerere University, Kampala, Uganda
16 shared publications Andrew Kambugu
Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda
15 shared publications- Andrew Kambugu
Infectious Diseases Institute, Makerere University, Kampala P.O. Box 22418, Uganda
11 shared publications - Joseph Musaazi
Infectious Diseases Institute, Makerere University
11 shared publications
Latest Publications
- Open Access
- 19 September 2026
- Published by Elsevier in SSRN Electronic Journal
Gender Equity and Inclusivity in Research Mentorship in Low-income or Middle-income Countries (LMICs): Findings from a Global Crowdsourcing Open Call and Scoping Review
Few women in research are able to advance into leadership positions in low-and middle-income countries (LMICs). Using evidence from a global crowdsourcing open call and scoping review we identified practical strategies to enhance gender equity and inclusivity in research mentorship in LMICs. The open call employed methods outlined in the WHO Special Programme for Research and Training in Tropical Diseases (TDR) Global practical guide on crowdsourcing in health research to solicit strategies to enhance equity in research mentorship programs, focusing on gender in LMICs. The scoping review followed the Arksey and O’Malley framework and PRISMA-ScR. Strategies synthesized from open call responses and existing literature were coded into themes. The quality of evidence for these themes was evaluated using the CERQual approach. The open call received 56 eligible submissions; the scoping review yielded 15 eligible studies focused on gender equity and inclusivity in research mentorship in LMICs. We identified the following four strategies to enhance gender equity in research mentorship: (1) take specific action to decrease implicit bias in research mentorship programs; (2) utilize asset-based approaches to increase mentees’ self-efficacy and confidence; (3) promote accomplishments, acknowledge wins, and appreciate mentee/mentor work efforts to sustain mentee interests and career progression; (4) utilize peer and reverse mentorship-built capacity for mentees serving as mentors and identify power imbalances. Increasing gender equity and inclusivity in research mentorship is a collective institutional responsibility. Addressing these barriers faced by underrepresented researchers play a critical role in fostering equity and inclusivity in research mentorship programs.
- 19 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessGender Equity and Inclusivity in Research Mentorship in Low-income or Middle-income Countries (LMICs): Findings from a Global Crowdsourcing Open Call and Scoping Review
Few women in research are able to advance into leadership positions in low-and middle-income countries (LMICs). Using evidence from a global crowdsourcing open call and scoping review we identified practical strategies to enhance gender equity and inclusivity in research mentorship in LMICs. The open call employed methods outlined in the WHO Special Programme for Research and Training in Tropical Diseases (TDR) Global practical guide on crowdsourcing in health research to solicit strategies to enhance equity in research mentorship programs, focusing on gender in LMICs. The scoping review followed the Arksey and O’Malley framework and PRISMA-ScR. Strategies synthesized from open call responses and existing literature were coded into themes. The quality of evidence for these themes was evaluated using the CERQual approach. The open call received 56 eligible submissions; the scoping review yielded 15 eligible studies focused on gender equity and inclusivity in research mentorship in LMICs. We identified the following four strategies to enhance gender equity in research mentorship: (1) take specific action to decrease implicit bias in research mentorship programs; (2) utilize asset-based approaches to increase mentees’ self-efficacy and confidence; (3) promote accomplishments, acknowledge wins, and appreciate mentee/mentor work efforts to sustain mentee interests and career progression; (4) utilize peer and reverse mentorship-built capacity for mentees serving as mentors and identify power imbalances. Increasing gender equity and inclusivity in research mentorship is a collective institutional responsibility. Addressing these barriers faced by underrepresented researchers play a critical role in fostering equity and inclusivity in research mentorship programs.
- Open Access
- 17 August 2026
- Published by Elsevier in SSRN Electronic Journal
Frailty and Other Ageing Phenotypes Among Older People Living With HIV Across a High- and Low-Income Setting: A Comparison of the HASA and GEPPO Cohorts
Background: The population of older people living with HIV is increasing worldwide. Comparative data on frailty and other geriatric syndromes across high- and low-income settings are limited. We compared frailty and other geriatric syndromes in two cohorts in Uganda and Italy.Methods: We performed a cross-sectional analysis of 500 HASA and 520 GEPPO participants (213 vs. 300 in the 65–75 subgroup). Frailty was assessed using the Fried phenotype. Analyses included overall cohort, subgroup analysis among participants aged 65–75 years, and age-sex standardized estimates. Multivariable ordinal logistic regression assessed whether residence in Uganda versus Italy was independently associated with higher frailty after adjustment for demographic and clinical characteristics.Findings: GEPPO participants were older, mostly male and had a higher prevalence of multimorbidity and polypharmacy (all p<0.01). Frailty prevalence was higher in GEPPO (13.3% vs. 8.4%; p<0.001), but did not differ in the 65–75 subgroup (6.6% vs. 8.5%; p=0.66). Of the frailty domains, shrinking predominated in HASA, while exhaustion, low physical activity, weakness, and slow walking speed were more common in GEPPO. Residence in Uganda was associated with higher odds of frailty (AOR 1·57, 95% CI 1·06–2·32), although this association was not statistically significant in the 65-75 subgroup (AOR 1.37, 95% CI 0.86–2.18; p=0.18).Interpretation: Frailty patterns differed between cohorts. In Uganda, weight loss (shrinking) was more relevant, whereas in Italy reduced physical performance, multimorbidity, and polypharmacy predominated. Interventions aimed at older people with HIV should consider these contextual differences when planning strategies to support healthy aging.
- 17 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessFrailty and Other Ageing Phenotypes Among Older People Living With HIV Across a High- and Low-Income Setting: A Comparison of the HASA and GEPPO Cohorts
Background: The population of older people living with HIV is increasing worldwide. Comparative data on frailty and other geriatric syndromes across high- and low-income settings are limited. We compared frailty and other geriatric syndromes in two cohorts in Uganda and Italy.Methods: We performed a cross-sectional analysis of 500 HASA and 520 GEPPO participants (213 vs. 300 in the 65–75 subgroup). Frailty was assessed using the Fried phenotype. Analyses included overall cohort, subgroup analysis among participants aged 65–75 years, and age-sex standardized estimates. Multivariable ordinal logistic regression assessed whether residence in Uganda versus Italy was independently associated with higher frailty after adjustment for demographic and clinical characteristics.Findings: GEPPO participants were older, mostly male and had a higher prevalence of multimorbidity and polypharmacy (all p<0.01). Frailty prevalence was higher in GEPPO (13.3% vs. 8.4%; p<0.001), but did not differ in the 65–75 subgroup (6.6% vs. 8.5%; p=0.66). Of the frailty domains, shrinking predominated in HASA, while exhaustion, low physical activity, weakness, and slow walking speed were more common in GEPPO. Residence in Uganda was associated with higher odds of frailty (AOR 1·57, 95% CI 1·06–2·32), although this association was not statistically significant in the 65-75 subgroup (AOR 1.37, 95% CI 0.86–2.18; p=0.18).Interpretation: Frailty patterns differed between cohorts. In Uganda, weight loss (shrinking) was more relevant, whereas in Italy reduced physical performance, multimorbidity, and polypharmacy predominated. Interventions aimed at older people with HIV should consider these contextual differences when planning strategies to support healthy aging.
- Open Access
- 24 July 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (7) , e0335299
Evaluating the feasibility and effectiveness of a capacity-building model to nurture junior independent clinical research investigators in Uganda
Background: Research capacity-building initiatives remain crucial to achieving Sustainable Development Goal 3 on health and well-being, especially in LMICs. We aimed to evaluate the effectiveness of the Infectious Disease Institute’s (IDI) Capacity-Building Model to nurture junior independent clinical research investigators in Uganda. Methods: From 13 th July 2021–06 th February 2023, we conducted a cross-sectional study using a mixed-methods approach to assess the extent to which the Capacity-Building Model was effective, feasible, and acceptable. For quantitative research, we conducted an online survey with 80 scholars (Master’s, PhD, and Post-doctoral fellows), comprising 20 alumni and 60 current scholars, to explore their experiences and perceptions as former and current scholars of the Capacity Building Unit (CBU) at IDI. For qualitative research, we purposively selected 20 scholars to participate in the in-depth interviews. Results: Participants reported that the capacity-building Model had a beneficial impact on their career progression, with 90% expressing a willingness to recommend it to others. The overall scientific benefit reported was 48.7%; this was significantly higher among continuing scholars than among alumni (56.7% vs 25.0%, respectively; p-value = 0.046). Additionally, 85% achieved their career goals, and 65% said it expanded their employment opportunities. Qualitative findings highlighted its significant positive impact on research training and professional development. Participants praised the Model’s emphasis on mentorship, with both scientific and non-scientific support proving crucial in guiding junior researchers through technical challenges, manuscript writing, and career planning. Soft skills training, dissemination platforms, and networking opportunities further contributed to scholars’ academic growth. Scholars benefited from robust institutional support, including access to research infrastructure, grantsmanship assistance, and administrative systems. However, challenges such as limited research funding, slow procurement processes, and delays in supervision hindered progress. The COVID-19 pandemic also disrupted mentorship and training. Participants recommended improvements in mentorship coordination, procurement efficiency, broader model visibility, and expansion to other universities and disciplines to enhance its effectiveness and sustainability. Conclusion: Overall, the Capacity-Building Model was highly acceptable among scholars; however, minor administrative challenges need to be addressed to further enhance learning. We recommend tailored, relevant scholarly programs to meet the evolving needs of emerging scientists and foster scholarly growth and research innovation in academic institutions, enabling them to tackle local public health challenges. Future research is required to assess the cost of capacity building and its sustainability.
- 24 July 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (7) , e0335299
Open AccessEvaluating the feasibility and effectiveness of a capacity-building model to nurture junior independent clinical research investigators in Uganda
Background: Research capacity-building initiatives remain crucial to achieving Sustainable Development Goal 3 on health and well-being, especially in LMICs. We aimed to evaluate the effectiveness of the Infectious Disease Institute’s (IDI) Capacity-Building Model to nurture junior independent clinical research investigators in Uganda. Methods: From 13 th July 2021–06 th February 2023, we conducted a cross-sectional study using a mixed-methods approach to assess the extent to which the Capacity-Building Model was effective, feasible, and acceptable. For quantitative research, we conducted an online survey with 80 scholars (Master’s, PhD, and Post-doctoral fellows), comprising 20 alumni and 60 current scholars, to explore their experiences and perceptions as former and current scholars of the Capacity Building Unit (CBU) at IDI. For qualitative research, we purposively selected 20 scholars to participate in the in-depth interviews. Results: Participants reported that the capacity-building Model had a beneficial impact on their career progression, with 90% expressing a willingness to recommend it to others. The overall scientific benefit reported was 48.7%; this was significantly higher among continuing scholars than among alumni (56.7% vs 25.0%, respectively; p-value = 0.046). Additionally, 85% achieved their career goals, and 65% said it expanded their employment opportunities. Qualitative findings highlighted its significant positive impact on research training and professional development. Participants praised the Model’s emphasis on mentorship, with both scientific and non-scientific support proving crucial in guiding junior researchers through technical challenges, manuscript writing, and career planning. Soft skills training, dissemination platforms, and networking opportunities further contributed to scholars’ academic growth. Scholars benefited from robust institutional support, including access to research infrastructure, grantsmanship assistance, and administrative systems. However, challenges such as limited research funding, slow procurement processes, and delays in supervision hindered progress. The COVID-19 pandemic also disrupted mentorship and training. Participants recommended improvements in mentorship coordination, procurement efficiency, broader model visibility, and expansion to other universities and disciplines to enhance its effectiveness and sustainability. Conclusion: Overall, the Capacity-Building Model was highly acceptable among scholars; however, minor administrative challenges need to be addressed to further enhance learning. We recommend tailored, relevant scholarly programs to meet the evolving needs of emerging scientists and foster scholarly growth and research innovation in academic institutions, enabling them to tackle local public health challenges. Future research is required to assess the cost of capacity building and its sustainability.
- Open Access
- 31 December 2025
- Published by Elsevier in The Journal of Aging Research & Lifestyle
- Vol. 15
Introducing the WHO ICOPE approach into HIV care: A perspective on healthy ageing in people living with HIV
- 31 December 2025
- Published by Elsevier in The Journal of Aging Research & Lifestyle
- Vol. 15
Open AccessIntroducing the WHO ICOPE approach into HIV care: A perspective on healthy ageing in people living with HIV
- Open Access
Evaluating The Feasibility and Effectiveness of a Capacity-Building Model to Nurture Junior Independent Clinical Research Investigators in Uganda
Background: Research capacity-building initiatives remain crucial to achieving Sustainable Development Goal 3 on health and well-being, especially in LMICs. We aimed to evaluate the effectiveness of the Infectious Disease Institute’s (IDI) capacity-building model to nurture junior independent clinical research investigators in Uganda. Methods: From 13 th July 2021 to 06 th February 2023, we conducted a trend analysis study using a mixed methods approach to assess the extent to which the Capacity-Building Model was effective, feasible, and acceptable. For quantitative research, we conducted an online survey with 80 trainees (Masters, PhD, and Postdoctoral fellows), comprising 20 alumni and 60 current trainees, to explore their experiences and perceptions as former and current scholars of the Capacity Building Unit (CBU) at IDI. For qualitative research, we purposively selected 20 trainees to participate in the in-depth interviews. Results: Participants reported that the capacity-building model had a beneficial impact on their career progression, with 90% expressing a willingness to recommend it to others. The overall scientific benefit reported was 48.7%; this was significantly higher among continuing scholars compared to alumni (56.7% vs 25.0%, respectively, p-value = 0.046). Additionally, 85% achieved their career goals, and 65% said it expanded their employment opportunities. Additionally, 85% achieved their career goals, and 65% said it expanded their employment opportunities. Qualitative findings highlighted its significant positive impact on research training and professional development. Participants praised the model’s emphasis on mentorship, with both scientific and non-scientific support proving crucial in guiding junior researchers through technical challenges, manuscript writing, and career planning. Soft skills training, dissemination platforms, and networking opportunities further contributed to scholars’ academic growth. Trainees benefited from robust institutional support, including access to research infrastructure, grantsmanship assistance, and administrative systems. However, challenges such as limited research funding, slow procurement processes, and supervisory delays hindered progress. The COVID-19 pandemic also disrupted mentorship and training. Participants recommended improvements in mentorship coordination, procurement efficiency, broader model visibility, and expansion to other universities and disciplines to enhance its effectiveness and sustainability. Conclusion: Overall, the acceptability of the Capacity-Building Model was high among scholars; however, minor administrative challenges need to be addressed to enhance learning further. We recommend tailored, relevant scholarly programs to meet the evolving needs of emerging scientists and foster scholarly growth and research innovation in academic institutions, enabling them to tackle local public health challenges. Future research is required to assess the cost of capacity building and its sustainability.
Open AccessEvaluating The Feasibility and Effectiveness of a Capacity-Building Model to Nurture Junior Independent Clinical Research Investigators in Uganda
Background: Research capacity-building initiatives remain crucial to achieving Sustainable Development Goal 3 on health and well-being, especially in LMICs. We aimed to evaluate the effectiveness of the Infectious Disease Institute’s (IDI) capacity-building model to nurture junior independent clinical research investigators in Uganda. Methods: From 13 th July 2021 to 06 th February 2023, we conducted a trend analysis study using a mixed methods approach to assess the extent to which the Capacity-Building Model was effective, feasible, and acceptable. For quantitative research, we conducted an online survey with 80 trainees (Masters, PhD, and Postdoctoral fellows), comprising 20 alumni and 60 current trainees, to explore their experiences and perceptions as former and current scholars of the Capacity Building Unit (CBU) at IDI. For qualitative research, we purposively selected 20 trainees to participate in the in-depth interviews. Results: Participants reported that the capacity-building model had a beneficial impact on their career progression, with 90% expressing a willingness to recommend it to others. The overall scientific benefit reported was 48.7%; this was significantly higher among continuing scholars compared to alumni (56.7% vs 25.0%, respectively, p-value = 0.046). Additionally, 85% achieved their career goals, and 65% said it expanded their employment opportunities. Additionally, 85% achieved their career goals, and 65% said it expanded their employment opportunities. Qualitative findings highlighted its significant positive impact on research training and professional development. Participants praised the model’s emphasis on mentorship, with both scientific and non-scientific support proving crucial in guiding junior researchers through technical challenges, manuscript writing, and career planning. Soft skills training, dissemination platforms, and networking opportunities further contributed to scholars’ academic growth. Trainees benefited from robust institutional support, including access to research infrastructure, grantsmanship assistance, and administrative systems. However, challenges such as limited research funding, slow procurement processes, and supervisory delays hindered progress. The COVID-19 pandemic also disrupted mentorship and training. Participants recommended improvements in mentorship coordination, procurement efficiency, broader model visibility, and expansion to other universities and disciplines to enhance its effectiveness and sustainability. Conclusion: Overall, the acceptability of the Capacity-Building Model was high among scholars; however, minor administrative challenges need to be addressed to enhance learning further. We recommend tailored, relevant scholarly programs to meet the evolving needs of emerging scientists and foster scholarly growth and research innovation in academic institutions, enabling them to tackle local public health challenges. Future research is required to assess the cost of capacity building and its sustainability.
- Open Access
Associations with Prevalent Sexually Transmitted Infection Prevalence among Young Women Domestic Workers in Central Uganda
Objective: Our study aimed to determine the prevalence and correlates of sexually transmitted infections (STIs) among adolescent girls and young women (AGYW) employed as household domestic workers in Kampala, Uganda. Methods: Ugandan AGYW aged 14-24 participated in a community-based cross-sectional study in the Kampala Metropolitan Area from November 2023 to March 2024. Self-collected vaginal swabs were tested for Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) using GeneXpert™. Testing for HIV and syphilis was performed using the Bioline™ HIV/syphilis Duo test. Correlates of STI prevalence were determined using modified Poisson regression. Results: Of 262 AGYW enrolled, the median age was 20 years (IQR 18-23), and 87 (33%) had an STI: Chlamydia trachomatis (27.5%), syphilis (5.7%), HIV (4.6%), and Neisseria gonorrhoea (1.5%). Overall, 14.9% had >1 STI. Of 12 AGYW with HIV, three (25%) were newly diagnosed, and 6/9 had detectable viral loads (≥1000 copies/ml). In the prior 12 months, 126 (48%) had received syndromic STI treatment, but only 35 (28%) notified their partners. Additionally, 102 (39%) had used emergency contraception, with 54% believing it was protective against STIs, including HIV. Factors associated with STI prevalence included receipt of non-cash (instead of salary) remuneration for domestic work (adjusted prevalence ratio [aPR] 2.26; 95% CI:1.04-4.92; P=0.040), lower education attainment (aPR 1.73; 95% CI: 1.16-2.57; P=0.007), alcohol consumption in past six months (aPR 1.72; 95% CI: 1.12-2.64; P=0.013) and transactional sex during the past six months (aPR 1.43; 95% CI: 1.01-2.04; P=0.045). Conversely, self-reported sexual abuse was negatively associated with STIs (aPR 0.48; 95% CI: 0.28-0.83; P=0.008). Conclusion: The high prevalence of undiagnosed STIs and unsuppressed HIV among AGYW domestic workers in Kampala highlights the urgent need to increase HIV/STI prevention, testing and treatment coverage for these underserved and vulnerable young women. Targeted interventions are needed to mitigate STI/HIV acquisition in this population. What is already known on this topic - summarise the state of scientific knowledge on this subject before you did your study, and why this study needed to be done.: Adolescent girls and young women (AGYW) in Uganda who are out of school and employed in household domestic work are a highly vulnerable population, often migrating from rural communities to cities with consequent social isolation, and are subject to unequal power dynamics with employers. This puts them at risk of intergenerational and transactional sex. The prevalence of STIs and HIV, and the associated socio-behavioural factors, have been poorly studied in this demographic, limiting the development of interventions for this group. What this study adds - summarise what we now know as a result of this study that we did not know before.: This cross-sectional study, which estimated STI and HIV prevalence among young females employed in household domestic work, found that one-third of AGYW domestic workers were diagnosed with at least one STI. The findings reveal a high burden of STIs and HIV, with many experiencing co-infections. Contributing factors such as poor working conditions, limited educational attainment and prevalent sexual behaviours associated with STIs– including transactional sex, sexual abuse, alcohol use, and inconsistent condom use– exacerbate their vulnerability. How this study might affect research, practice, or policy - summarise the implications of this study.: This research provides insights into STI and HIV risks for vulnerable AGYW employed in domestic work. It highlights the need for tailored HIV and STI interventions that focus on increased awareness, economic and educational empowerment, improved working conditions, socio-behavioural changes, legal redress, as well as expanded access to STI/HIV testing and treatment services for this hard-to-reach population.
Open AccessAssociations with Prevalent Sexually Transmitted Infection Prevalence among Young Women Domestic Workers in Central Uganda
Objective: Our study aimed to determine the prevalence and correlates of sexually transmitted infections (STIs) among adolescent girls and young women (AGYW) employed as household domestic workers in Kampala, Uganda. Methods: Ugandan AGYW aged 14-24 participated in a community-based cross-sectional study in the Kampala Metropolitan Area from November 2023 to March 2024. Self-collected vaginal swabs were tested for Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) using GeneXpert™. Testing for HIV and syphilis was performed using the Bioline™ HIV/syphilis Duo test. Correlates of STI prevalence were determined using modified Poisson regression. Results: Of 262 AGYW enrolled, the median age was 20 years (IQR 18-23), and 87 (33%) had an STI: Chlamydia trachomatis (27.5%), syphilis (5.7%), HIV (4.6%), and Neisseria gonorrhoea (1.5%). Overall, 14.9% had >1 STI. Of 12 AGYW with HIV, three (25%) were newly diagnosed, and 6/9 had detectable viral loads (≥1000 copies/ml). In the prior 12 months, 126 (48%) had received syndromic STI treatment, but only 35 (28%) notified their partners. Additionally, 102 (39%) had used emergency contraception, with 54% believing it was protective against STIs, including HIV. Factors associated with STI prevalence included receipt of non-cash (instead of salary) remuneration for domestic work (adjusted prevalence ratio [aPR] 2.26; 95% CI:1.04-4.92; P=0.040), lower education attainment (aPR 1.73; 95% CI: 1.16-2.57; P=0.007), alcohol consumption in past six months (aPR 1.72; 95% CI: 1.12-2.64; P=0.013) and transactional sex during the past six months (aPR 1.43; 95% CI: 1.01-2.04; P=0.045). Conversely, self-reported sexual abuse was negatively associated with STIs (aPR 0.48; 95% CI: 0.28-0.83; P=0.008). Conclusion: The high prevalence of undiagnosed STIs and unsuppressed HIV among AGYW domestic workers in Kampala highlights the urgent need to increase HIV/STI prevention, testing and treatment coverage for these underserved and vulnerable young women. Targeted interventions are needed to mitigate STI/HIV acquisition in this population. What is already known on this topic - summarise the state of scientific knowledge on this subject before you did your study, and why this study needed to be done.: Adolescent girls and young women (AGYW) in Uganda who are out of school and employed in household domestic work are a highly vulnerable population, often migrating from rural communities to cities with consequent social isolation, and are subject to unequal power dynamics with employers. This puts them at risk of intergenerational and transactional sex. The prevalence of STIs and HIV, and the associated socio-behavioural factors, have been poorly studied in this demographic, limiting the development of interventions for this group. What this study adds - summarise what we now know as a result of this study that we did not know before.: This cross-sectional study, which estimated STI and HIV prevalence among young females employed in household domestic work, found that one-third of AGYW domestic workers were diagnosed with at least one STI. The findings reveal a high burden of STIs and HIV, with many experiencing co-infections. Contributing factors such as poor working conditions, limited educational attainment and prevalent sexual behaviours associated with STIs– including transactional sex, sexual abuse, alcohol use, and inconsistent condom use– exacerbate their vulnerability. How this study might affect research, practice, or policy - summarise the implications of this study.: This research provides insights into STI and HIV risks for vulnerable AGYW employed in domestic work. It highlights the need for tailored HIV and STI interventions that focus on increased awareness, economic and educational empowerment, improved working conditions, socio-behavioural changes, legal redress, as well as expanded access to STI/HIV testing and treatment services for this hard-to-reach population.
- Open Access
- 24 January 2025
- Published by Wiley in HIV Medicine
- Vol. 26 (4) , 592-605
A programmatic assessment of dolutegravir adverse events and discontinuations in Uganda
Introduction: Dolutegravir is now extensively used in sub‐Saharan Africa as a preferred component of antiretroviral therapy (ART). There is a paucity of large studies using routinely collected data from African people living with HIV on dolutegravir‐based regimens to inform HIV programmes. We reviewed data in a large programme clinic of people living with HIV on dolutegravir to determine the real‐world safety and tolerability of dolutegravir and to describe drivers of treatment discontinuation.Methods: We carried out a retrospective dynamic cohort analysis of people living with HIV who started on or switched to dolutegravir‐based ART at the Infectious Diseases Institute in Kampala, Uganda, between February 2017 and December 2020. Types of adverse events (AEs) were classified according to the Medical Dictionary for Regulatory Activities. Incident rates for AEs and treatment discontinuation were determined using Cox proportional hazard methods.Results: Of 4529 people living with HIV started on or switched to dolutegravir, 2094 (45.9%) were female, and the median age was 49 years (interquartile range [IQR] 41–56). During 8907.93 person‐years (PY) of follow‐up, 1069 (23.6%; 95% confidence interval [CI] 22.4–24.8) people living with HIV had an AE, at a rate of 10.43 per 1000 PY (95% CI 9.77–11.14). Neuropsychiatric, gastrointestinal, and endocrine AEs were most common. The main AEs driving dolutegravir discontinuation were hyperglycaemia (140/356; 39.3%) and erectile dysfunction (19/356; 5.3%). Only 1.2% (4/356) of the dolutegravir discontinuations were because of neuropsychiatric AEs. Being female (adjusted hazard ratio [aHR] 1.35; 95% CI 1.02–1.78) and previous use of stavudine (aHR 1.46; 95% CI 1.04–2.05) were the main predictors of neuropsychiatric AEs. Risk factors for hyperglycaemia included being overweight (aHR 1.66; 95% CI 1.11–2.47) or obese (aHR 1.84; 95% CI 1.12–3.05), having hypertension (aHR 1.92; 95% CI 1.35–2.73), having diabetes mellitus (aHR 12.6; 95% CI 8.34–19.1), and taking previous ART containing zidovudine (aHR 1.76; 95% CI 1.19–2.59) or stavudine (aHR 1.68; 95% CI 1.15–2.44). These risk factors for hyperglycaemia were also the main drivers of dolutegravir discontinuation.Conclusion: AEs were common in this African cohort, and dolutegravir discontinuation was driven by hyperglycaemia and erectile dysfunction. Previous use of older ART with known mitochondrial toxicity was associated with neuropsychiatric AEs and hyperglycaemia. African countries used these drugs for longer periods, and this may contribute to this risk.
- 24 January 2025
- Published by Wiley in HIV Medicine
- Vol. 26 (4) , 592-605
Open AccessA programmatic assessment of dolutegravir adverse events and discontinuations in Uganda
Introduction: Dolutegravir is now extensively used in sub‐Saharan Africa as a preferred component of antiretroviral therapy (ART). There is a paucity of large studies using routinely collected data from African people living with HIV on dolutegravir‐based regimens to inform HIV programmes. We reviewed data in a large programme clinic of people living with HIV on dolutegravir to determine the real‐world safety and tolerability of dolutegravir and to describe drivers of treatment discontinuation.Methods: We carried out a retrospective dynamic cohort analysis of people living with HIV who started on or switched to dolutegravir‐based ART at the Infectious Diseases Institute in Kampala, Uganda, between February 2017 and December 2020. Types of adverse events (AEs) were classified according to the Medical Dictionary for Regulatory Activities. Incident rates for AEs and treatment discontinuation were determined using Cox proportional hazard methods.Results: Of 4529 people living with HIV started on or switched to dolutegravir, 2094 (45.9%) were female, and the median age was 49 years (interquartile range [IQR] 41–56). During 8907.93 person‐years (PY) of follow‐up, 1069 (23.6%; 95% confidence interval [CI] 22.4–24.8) people living with HIV had an AE, at a rate of 10.43 per 1000 PY (95% CI 9.77–11.14). Neuropsychiatric, gastrointestinal, and endocrine AEs were most common. The main AEs driving dolutegravir discontinuation were hyperglycaemia (140/356; 39.3%) and erectile dysfunction (19/356; 5.3%). Only 1.2% (4/356) of the dolutegravir discontinuations were because of neuropsychiatric AEs. Being female (adjusted hazard ratio [aHR] 1.35; 95% CI 1.02–1.78) and previous use of stavudine (aHR 1.46; 95% CI 1.04–2.05) were the main predictors of neuropsychiatric AEs. Risk factors for hyperglycaemia included being overweight (aHR 1.66; 95% CI 1.11–2.47) or obese (aHR 1.84; 95% CI 1.12–3.05), having hypertension (aHR 1.92; 95% CI 1.35–2.73), having diabetes mellitus (aHR 12.6; 95% CI 8.34–19.1), and taking previous ART containing zidovudine (aHR 1.76; 95% CI 1.19–2.59) or stavudine (aHR 1.68; 95% CI 1.15–2.44). These risk factors for hyperglycaemia were also the main drivers of dolutegravir discontinuation.Conclusion: AEs were common in this African cohort, and dolutegravir discontinuation was driven by hyperglycaemia and erectile dysfunction. Previous use of older ART with known mitochondrial toxicity was associated with neuropsychiatric AEs and hyperglycaemia. African countries used these drugs for longer periods, and this may contribute to this risk.
- Open Access
Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol
Introduction: Tuberculosis (TB) is the leading infectious cause of death globally. Despite WHO recommendations for TB preventive therapy (TPT), challenges persist, including incompletion of treatment and adverse drug reactions (ADRs). There is limited data on the 3-month isoniazid and rifapentine (3HP) pharmacokinetics, pharmacogenomics and their relation with ADRs. Our study aims to describe the pharmacokinetic and pharmacogenomics of 3HP used for TPT, the ADRs and their association with completion rates, and TPT outcomes, providing vital insights for TB control strategies in resource-limited settings.Methods: This is an observational cohort study with a nested case–control study. We enrolled consecutive patients who had been initiated on TPT using the 3HP regimen. These are followed up biweekly and then monthly during the active phase of treatment and 3 monthly for 2 years following completion of TPT. ADR evaluation includes clinical assessment and liver function tests. Cases are selected from those who experience ADRs and controls from those who do not. Serum isoniazid and rifapentine concentrations are measured and pharmacogenomic analysis for NAT2, AADAC and CYP2E1 polymorphisms are done. Participants are followed up for 2 years to determine TPT outcomes.Analysis: The safety profile of 3HP will be assessed using descriptive statistics, including proportions of patients experiencing ADRs and grade 3 or above events related to treatment. χ2tests and regression models will determine predictors of ADRs and their impact on treatment completion. Pharmacokinetic-pharmacodynamic modelling will establish population parameters and factors influencing rifapentine and isoniazid concentrations.Ethics and dissemination: Ethical approval of this study inclusive of all the appropriate documents was obtained from the Infectious Diseases Institute Research and Ethics Committee and the Uganda National Council of Science and Technology. The study adheres to legal, ethical and Good Clinical Practice (GCP) guidelines. Deidentified genotype data from 300 patients will be shared after publication. The protocol and phenotype data will be publicly accessible. Abstracts will be submitted to conferences, and a manuscript will be published poststudy.
Open AccessClinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol
Introduction: Tuberculosis (TB) is the leading infectious cause of death globally. Despite WHO recommendations for TB preventive therapy (TPT), challenges persist, including incompletion of treatment and adverse drug reactions (ADRs). There is limited data on the 3-month isoniazid and rifapentine (3HP) pharmacokinetics, pharmacogenomics and their relation with ADRs. Our study aims to describe the pharmacokinetic and pharmacogenomics of 3HP used for TPT, the ADRs and their association with completion rates, and TPT outcomes, providing vital insights for TB control strategies in resource-limited settings.Methods: This is an observational cohort study with a nested case–control study. We enrolled consecutive patients who had been initiated on TPT using the 3HP regimen. These are followed up biweekly and then monthly during the active phase of treatment and 3 monthly for 2 years following completion of TPT. ADR evaluation includes clinical assessment and liver function tests. Cases are selected from those who experience ADRs and controls from those who do not. Serum isoniazid and rifapentine concentrations are measured and pharmacogenomic analysis for NAT2, AADAC and CYP2E1 polymorphisms are done. Participants are followed up for 2 years to determine TPT outcomes.Analysis: The safety profile of 3HP will be assessed using descriptive statistics, including proportions of patients experiencing ADRs and grade 3 or above events related to treatment. χ2tests and regression models will determine predictors of ADRs and their impact on treatment completion. Pharmacokinetic-pharmacodynamic modelling will establish population parameters and factors influencing rifapentine and isoniazid concentrations.Ethics and dissemination: Ethical approval of this study inclusive of all the appropriate documents was obtained from the Infectious Diseases Institute Research and Ethics Committee and the Uganda National Council of Science and Technology. The study adheres to legal, ethical and Good Clinical Practice (GCP) guidelines. Deidentified genotype data from 300 patients will be shared after publication. The protocol and phenotype data will be publicly accessible. Abstracts will be submitted to conferences, and a manuscript will be published poststudy.
- Open Access
- 2 October 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (11) , 1915-1923
Interim analysis, a tool to enhance efficiency of pharmacokinetic studies: Pharmacokinetics of rifampicin in lactating mother–infant pairs
Pharmacokinetic studies are important for understanding drug disposition in the human body. However, pregnant and lactating women are often excluded from primary pharmacokinetic studies and as such there is often limited dosing information regarding drug use in pregnant and/or lactating women. The objectives of this interim analysis were to define the transfer of rifampicin to a breastfed infant and to determine the area under the concentration–time curve of rifampicin in maternal plasma, breastmilk and infant plasma. Performing this interim analysis enabled us to substantiate whether prior assumptions we made on several study design issues including patient sample size and pharmacokinetic sampling times held and whether we needed to amend our protocol or not. We enrolled lactating mothers on treatment for tuberculosis with their breastfeeding infants (below 12 months of age), performed intensive pharmacokinetic sampling (0–24 h post‐dose) on plasma samples from both the mother, infant(s) and breastmilk samples from the mother on two separate occasions (once during the initiation phase and another during the continuation phase of tuberculosis treatment). The initial study design, including sampling times, was informed by a stochastic simulation and estimation exercise, with very limited prior breastmilk data. An interim analysis after recruiting 6 mother–infant pairs ascertained that our initial assumptions were ideal for achieving our study objectives and no amendments to the sampling times were necessary. Initial data from 6 mother–infant pairs show that rifampicin penetrates breastmilk with an approximate milk‐to‐plasma ratio of 0.169 and 0.189 on two separate visits. However, it was undetectable in most infants.
- 2 October 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (11) , 1915-1923
Open AccessInterim analysis, a tool to enhance efficiency of pharmacokinetic studies: Pharmacokinetics of rifampicin in lactating mother–infant pairs
Pharmacokinetic studies are important for understanding drug disposition in the human body. However, pregnant and lactating women are often excluded from primary pharmacokinetic studies and as such there is often limited dosing information regarding drug use in pregnant and/or lactating women. The objectives of this interim analysis were to define the transfer of rifampicin to a breastfed infant and to determine the area under the concentration–time curve of rifampicin in maternal plasma, breastmilk and infant plasma. Performing this interim analysis enabled us to substantiate whether prior assumptions we made on several study design issues including patient sample size and pharmacokinetic sampling times held and whether we needed to amend our protocol or not. We enrolled lactating mothers on treatment for tuberculosis with their breastfeeding infants (below 12 months of age), performed intensive pharmacokinetic sampling (0–24 h post‐dose) on plasma samples from both the mother, infant(s) and breastmilk samples from the mother on two separate occasions (once during the initiation phase and another during the continuation phase of tuberculosis treatment). The initial study design, including sampling times, was informed by a stochastic simulation and estimation exercise, with very limited prior breastmilk data. An interim analysis after recruiting 6 mother–infant pairs ascertained that our initial assumptions were ideal for achieving our study objectives and no amendments to the sampling times were necessary. Initial data from 6 mother–infant pairs show that rifampicin penetrates breastmilk with an approximate milk‐to‐plasma ratio of 0.169 and 0.189 on two separate visits. However, it was undetectable in most infants.
- Open Access
- 20 September 2024
- Published by Taylor & Francis in International Journal of Social Research Methodology
- Vol. 28 (4) , 425-434
Adapting citizens’ jury methodology for use in Uganda: use of creative arts as a tool in deliberative, participatory research
- 20 September 2024
- Published by Taylor & Francis in International Journal of Social Research Methodology
- Vol. 28 (4) , 425-434
Open AccessAdapting citizens’ jury methodology for use in Uganda: use of creative arts as a tool in deliberative, participatory research